1Department of Gastroenterology and Hepatology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
2Gastroenterology and Hepatology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
3Department of Gastroenterology and Hepatology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
4Surgical Oncology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Introduction: It is long known that vitamin D deficiency was common in patients with liver disease, but little is known on the therapeutic effects of vitamin D, especially in patients with chronic liver disease. In this study, we aimed to systematically review the literatures and study the evidences in which the effects of vitamin D supplementation had been investigated on the severity of chronic liver disease or liver cirrhosis. Methods: A systematic literature search was performed by using the following key terms “vitamin D supplementation” and “chronic liver disease” in the PubMed, Scopus and Google scholar to find relevant articles. After collecting the eligible documents, data were extracted and described based on the purpose of this review. Result: Of total 196 articles found, only 7 relevant documents with 518 studied patients were included. The results of this study showed that the levels of 25(OH) D were considerably lower in patients with chronic liver disease. Findings showed that vitamin D supplementation can rise up the mean serum level of 25(OH) D in patients with severe vitamin D deficiency, especially patients with liver cirrhosis. Conclusion:The results of this review showed that vitamin D deficiency is associated with the severity of liver disease and may have prognostic value in the assessment of liver disease. Also, it was shown that vitamin D supplementation may be helpful for the treatment of liver disease at least in certain groups of patients.
Introduction Vitamin D is a fat-soluble sterol that is synthesized in the liver and has various functions in the body (1). In addition to its role in bone health, vitamin D plays a role in the balance of immune system and dealing with viruses and bacterial agents as well as the pathogenesis of autoimmune diseases (2,3). Recent studies have shown that vitamin D may have role in the progression of chronic liver disease (4,5). Due to the severity of liver damage and impaired synthesis of certain proteins, patients with vitamin D deficiency are at greater risk of chronic liver disease (6,7). It appears that hepatitis C virus (HCV) inhibits the synthesis of 25 (OH) D by altering the fat metabolism; moreover, it prevents the production of pre-vitamin D (8). On the other hand, vitamin D deficiency is associated with the severity of liver disease and fibrosis in chronic hepatitis C (CHC) (9,10). It has been shown that the change in the metabolism of 25 (OH) D is associated with stiffness of the liver in chronic liver disease, and vitamin D plays a role in the onset of fibrosis (11). It has also been shown that low levels of vitamin D receptor (VDR) are the most important factor influencing fibrosis (12). Findings have also suggested that VDR polymorphisms may be associated with the development of cirrhosis (13). In addition, in patients with CHC, vitamin D deficiency was associated with reduced viral response to treatment with pegylated-interferon (PEG-IFN) / ribavirin (RBV) (14). In some studies, the addition of vitamin D to the treatment regimen of PEG/RBV has resulted in increased therapeutic response in CHC (15). The results of some studies show that vitamin D inhibits replication of the HCV virus, which represents the antiviral effect of this vitamin; moreover, it has synergistic antiviral effect with interferon (16). It seems that 1, 25 (OH) D has anti fibrosis effect that is mainly mediated by bone marrow stem cells. It is shown that 1, 25 (OH) D can increase VDR and inhibits proliferation of stellate cell and also induce the expression of cyclin D1 (inhibitor of metalloproteinase and collagen) (17). In addition, vitamin D has the ability to reduce the production of smooth muscle actin and collagen and thus can inhibit the progression of liver cirrhosis induced by thioacetamide (18). All of these evidences suggest that vitamin D is an anti-fibrosis agent. Available evidences suggest that the addition of vitamin D to a normal diet may improve the prognosis of patients with chronic hepatitis (19). According to the U.S. National Institutes of Health for clinical trials (https://clinicaltrials.gov/), many trials are under study to evaluate the effects of vitamin D supplementation on different disorders, particularly in cirrhotic patients. In this survey, we aim to systematically review the evidences in which the effects of vitamin D or vitamin D supplementation had been investigated on the severity of chronic liver disease or liver cirrhosis.
Methods Search methods We conducted a systematic literature search to evaluate the effects of vitamin D supplementation on the severity of chronic liver disease in patients with liver cirrhosis. For this purpose, we independently searched PubMed, Scopus, and Google scholar for “vitamin D supplementation” and “liver cirrhosis” in the title, abstract and keywords of documents. To perform literature search in PubMed, following search strategy (((vitamin D supplementation OR vitamin D supplement OR vitamin D therapy OR vitamin D OR cholecalciferol)) AND (chronic liver disease OR chronic hepatitis OR cirrhosis OR liver cirrhosis OR fibrosis OR liver fibrosis)) AND (severity OR intensity) was used with customized search wherein the records were limited to those articles with English language. To find relevant articles in the Scopus, we used a similar search method. For this purpose, vitamin D supplementation was searched in the Scopus and liver cirrhosis was searched within the results. Afterwards, we limited the records to those articles published in English language. Google scholar was also searched for the described key terms. In addition to the described electronic databases, we conducted a manual search of the reference lists to minimize the risk of data loss, and also to include other potentially eligible documents.
Study selection and inclusion/exclusion criteria We did not define time limitation for the collection of articles during literature selection. Hence, all relevant documents to the main purpose of this survey wherein the effects of vitamin D therapy or vitamin D supplementation had been studied on the severity of liver cirrhosis were included. Articles with nearly all types of study design including controlled clinical trial, observational, cross-sectionals, comparative, prospective cohorts, evaluation and multicenter studies were included in this study to collect all available data on the issue. Moreover, conference abstracts or presentations, book sections, letters, review articles and meta-analysis were excluded from further assessment. However, the search was limited to only those articles with English language to avoid any misconceptions during data analysis. Documents with subject and/or language irrelevancy were excluded in the first step of article selection. Likewise, duplicated documents as well as articles with inadequate data were excluded from further evaluation.
Data extraction All available information including author’s name, publication date, country of study, and studied sample size in each study were extracted. Based on the main purpose of this study, other necessary information including target population, age and sex ratio of studied population, type of study design, methods of assessment, and the key findings of each study were extracted and described. According to inclusion/exclusion criteria, eligible articles among the collected documents were identified and data were extracted by two investigators independently. To avoid potential errors and probable miscalculation during data processing, any likely disagreements between the investigators were resolved in each step prior to further data processing. All processes including methods of literature search, selection of article, and data processing and qualitative analysis were performed according to the protocol recommended in PRISMA checklist 2009 (20).
Measured variables Various methods including standard biochemical examinations, serological analysis, liver biopsy or imaging, isotope-dilution liquid chromatography–tandem mass spectrometry, immunonephelometry, and chemiluminescent microparticle immunoassay had been used for clinical evaluation of the studied patients in the selected literatures. The variables of interest that were extracted and compared included the levels of vitamin D2 and D3, liver function, and liver enzymes. Other variables that had been evaluated in the included literatures were serum levels of albumin, bilirubin, aminotransferases, alkaline phosphatase and gamma-glutamyl transferase.
Results Literature search results Nearly 194 documents were collected by search in PubMed, Scopus, and Google scholar. Of these articles, 131 potentially relevant articles were in PubMed, 51 were in Scopus and 12 were in Google scholar. Two other potentially relevant articles were also found through reference list screening at final assessment of included documents. Of all collected literatures, 75 articles were disqualified in the first step after reviewing the title and abstract due to subject irrelevancy. Thirty two additional documents were also excluded from collected document pool by limiting the results to studies conducted on human. In addition, 28 documents were excluded due to language irrelevancy. Other 21 articles were further excluded due to data inadequacy. Likewise, 19 review articles were excluded from additional assessment. Finally, full text of 21 articles were collected and used for data collection. After reviewing the full text of eligible documents, only 7 relevant articles that fully met the defined inclusion/exclusion criteria and contained data in which the effects of vitamin D supplementation had been evaluated on the severity of chronic liver disease were included and used for data processing. The step by step process of literature search and selection is illustrated in Figure 1.
General characteristics of the included articles The total number of patients studied for the effect of vitamin D or vitamin D supplementation on the severity of chronic liver disease was 518. The number of studied patients varied from 17 in retrospective study to 158 in a prospective cohort study among the included documents. All patients had various kinds of chronic liver disease, particularly liver cirrhosis before vitamin D therapy. The studied populations were both male and female patients with confirmed chronic liver disease or liver cirrhosis, and of these patients, 270 were male and 187 were female; moreover, the sex of 61 patients had not been reported in some articles. The age of patients varied from 25 to 84 among the included documents. The most old and recent articles that were included in this survey had been published in 2010 and 2015, respectively. Documents that were used for data extraction and qualitative evaluation included 1 retrospective, 2 prospective cohorts, 2 cross-sectional, 1 case-control and 1 pilot study. General information of articles included in this survey is demonstrated in Table 1 in their chronological order of published time. Study findings As expected, the results of this survey showed that patients with liver cirrhosis had considerably lower 25(OH) D3 levels compared to healthy individuals without complications. Qualitative assessment of the results described in the included documents showed that there is correlation between vitamin D level and the degree of liver disease. Findings suggested that vitamin D supplementation can result in up to 141.1% increase in the mean serum level of 25(OH) D in patients with severe vitamin D deficiency. Also, it was shown that only a single dose of oral D3 supplementation (300 000 IU) could increase 25(OH) D plasma levels to standard values in all of the patients with liver cirrhosis. Findings also showed that serum levels of 25(OH) D3 decrease with the progress of liver disease, especially liver cirrhosis. Although the results showed that vitamin D supplementation may alter biochemical indices of the liver, but there were no significant association between the plasma levels of 25(OH) D and biochemical liver tests, as well as with fibrosis stage in some studies. Similarly, the results of some studies demonstrated that vitamin D levels did not differ in patients who were under treatment with vitamin D and those who did not receive supplementation. Although the results were contradictory, but the results of studies demonstrated that vitamin D supplementation may be beneficial for the treatment of chronic liver disease at least at early stages of liver disease. Main findings of included documents as well as methods and variables are summarized in Table 2.
Discussion Chronic liver diseases refer to liver pathologies including chronic hepatitis, and cirrhosis of the liver. These diseases are slowly progressive pathologies that may last over several months, and can cause several complications in the liver including hepatic encephalopathy, and hepatocellular carcinoma. Previously, it has been shown that chronic liver diseases may arise from vitamin D deficiency as a result of disorders in the vitamin D absorption, decreased synthesis or inadequate dietary vitamin D intake from foods or other supplements. Malabsorption may sometimes be attributable to the hypertension in the portal vein system caused by the liver disease. Findings suggested that there is association between lower vitamin D levels with the incidence of chronic liver disease (28). Also, it is demonstrated that patients with vitamin D deficiency are at greater risk of liver disease and fibrosis. In addition, the progression of fibrosis and hepatic inflammation is rather rapid in these patients. On the other hand, it is suggested that adequate levels of vitamin D can decrease the incidence of fibrosis in patients with CHC (29). Despite correlation between vitamin D deficiency and occurrence or progression of liver dysfunction, the evidences still do not support the effectiveness of vitamin D supplementation for the treatment of liver disease, especially liver cirrhosis in clinical practice, and further studies is suggested to evaluate the effects of vitamin D therapy in chronic liver disease (30). Recent researches suggested that nutritional support, especially adequate intake of vitamin D supplementation may be helpful for patients with various forms of chronic liver disease (31,32). The results of present review also indicated that the relapse rate was significantly decreased in patients with CHC who were under treatment with alfacalcidol supplementation as a source of vitamin D (23). Moreover, findings have shown that vitamin D supplementation can considerably improve depressive symptoms in female patients with chronic liver disease (33,34). Although the results were promising, but there were some studies that did not support such findings and showed that vitamin D supplementation may normalize the level of 25(OH)D in all patients with various types of chronic liver disease, but biochemical markers of liver necroinflammation may not be affected immediately (22,26). Since, the oldest articles included in this review had been published in 2010; therefore, it is clear that vitamin D therapy is a recent issue for the treatment of chronic liver disease, and enough researches had not been conducted regarding the efficacy of vitamin D supplementation in the treatment or lowering the progression of chronic liver disease (35). Although the findings as well as the results of this review are suggestive for the possible role of vitamin D therapy for the management of liver disease at least for certain groups of patients, but so far the exact role and possible efficacy of vitamin D supplementation has not been investigated in clinical trials. According to the U.S. National Institutes of Health for clinical trials, some trials on the role of vitamin D therapy in patients with chronic liver disease are in progress. The major limitations of this review include lack of enough documents so that most of data extracted from studies were only a small part of the trials wherein the effects of vitamin D supplementation had been investigated on the severity of chronic liver disease in a limited number of populations. Therefore, the exact role and also assessing the effectiveness of vitamin D supplementation on the severity of chronic liver disease requires further investigations.
Conclusion The results of studies show that vitamin D supplementation may be beneficial for the management of liver disease at least in certain groups of patients. Also, it was shown that vitamin D deficiency is associated with the severity of liver disease and can be considered as an independent prognostic parameter in liver disease, indicating that 25(OH)D3 levels decrease with the progress of liver cirrhosis while vitamin D therapy may or may not improve the progression of disease.
Conflict of Interest The authors declare no conflict of interest.
Wacker M, Holick MF. Sunlight and Vitamin D: A global perspective for health. Dermatoendocrinol. 2013;5:51-108.
Miragliotta G, Miragliotta L. Vitamin D and infectious diseases. Endocr Metab Immune Disord Drug Targets. 2014;14:267-271.
Delvin E, Souberbielle JC, Viard JP, et al. Role of vitamin D in acquired immune and autoimmune diseases. Crit Rev Clin Lab Sci. 2014;51:232-247.
Bitetto D, Fabris C, Fornasiere E, et al. Vitamin D supplementation improves response to antiviral treatment for recurrent hepatitis C. Transpl Int. 2011;24:43-50.
Foroughi M, Maghsoudi Z, Ghiasvand R, et al. Effect of Vitamin D Supplementation on C-reactive Protein in Patients with Nonalcoholic Fatty Liver. Int J Prev Med. 2014;5:969-975.
Nair S. Vitamin d deficiency and liver disease. Gastroenterol Hepatol (N Y). 2010;6:491-493.
Luong K, Nguyen LT. Theoretical basis of a beneficial role for vitamin D in viral hepatitis. World J Gastroenterol. 2012;18:5338-5350.
Webb AR. Who, what, where and when-influences on cutaneous vitamin D synthesis. Prog Biophys Mol Biol. 2006;92:17-25.
El Husseiny NM, Fahmy HM, Mohamed WA, et al. Relationship between vitamin D and IL-23, IL-17 and macrophage chemoattractant protein-1 as markers of fibrosis in hepatitis C virus Egyptians. World J Hepatol. 2012;4:242-247.
Baur K, Mertens JC, Schmitt J, et al. Combined effect of 25-OH vitamin D plasma levels and genetic vitamin D receptor (NR 1I1) variants on fibrosis progression rate in HCV patients. Liver Liver Int. 2012;32:635-643.
Grünhage F, Hochrath K, Krawczyk M, et al. Common genetic variation in vitamin D metabolism is associated with liver stiffness. Hepatology. 2012;56:1883-1891.
Ding N, Yu RT, Subramaniam N, et al. A vitamin D receptor/SMAD genomic circuit gates hepatic fibrotic response. Cell. 2013;153:601-613.
Tanaka A, Nezu S, Uegaki S, et al. Vitamin D receptor polymorphisms are associated with increased susceptibility to primary biliary cirrhosis in Japanese and Italian populations. J Hepatol. 2009;50:1202-1209.
Kitson MT, Sarrazin C, Toniutto P, et al. Vitamin D level and sustained virologic response to interferon-based antiviral therapy in chronic hepatitis C: a systematic review and meta-analysis. J Hepatol. 2014;61:1247-1252.
Yokoyama S, Takahashi S, Kawakami Y, et al. Effect of vitamin D supplementation on pegylated interferon/ribavirin therapy for chronic hepatitis C genotype 1b: a randomized controlled trial. J Viral Hepat. 2014;21:348-356.
Villar LM, Del Campo JA, Ranchal I, et al. Association between vitamin D and hepatitis C virus infection: a meta-analysis. World J Gastroenterol. 2013;19:5917-5924.
Abramovitch S, Dahan-Bachar L, Sharvit E, et al. Vitamin D inhibits proliferation and profibrotic marker expression in hepatic stellate cells and decreases thioacetamide-induced liver fibrosis in rats. Gut. 2011;60:1728-1737.
Song BJ, Rockey DC. Status of research on vitamin D supplementation in treating or preventing liver fibrosis. Liver Int. 2013;33:653-655.
Iruzubieta P, Teran A, Crespo J, et al. Vitamin D deficiency in chronic liver disease. World J Hepatol. 2014;6:901-915.
Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med. 2009;151:W65-94.
Finkelmeier F, Kronenberger B, Zeuzem S, et al. Low 25-Hydroxyvitamin D Levels Are Associated with Infections and Mortality in Patients with Cirrhosis. PLoS One. 2015;10:e0132119.
Ladero JM, Torrejon MJ, Sanchez-Pobre P, et al. Vitamin D deficiency and vitamin D therapy in chronic hepatitis C. Ann Hepatol. 2013;12:199-204.
Atsukawa M, Tsubota A, Shimada N, et al. Efficacy of Alfacalcidol on PEG-IFN/ Ribavirin Combination Therapy for Elderly Patients With Chronic Hepatitis C: A Pilot Study. Hepat Mon. 2013;13:e14872.
Malham M, Peter Jorgensen S, Lauridsen AL, et al. The effect of a single oral megadose of vitamin D provided as either ergocalciferol (D(2)) or cholecalciferol (D(3)) in alcoholic liver cirrhosis. Eur J Gastroenterol Hepatol. 2012;24:172-178.
Corey KE, Zheng H, Mendez-Navarro J, et al. Serum vitamin D levels are not predictive of the progression of chronic liver disease in hepatitis C patients with advanced fibrosis. PLoS One. 2012;7:e27144.
Malham M, Jorgensen SP, Ott P, et al. Vitamin D deficiency in cirrhosis relates to liver dysfunction rather than aetiology. World J Gastroenterol. 2011 21;17:922-925.
Rode A, Fourlanos S, Nicoll A. Oral vitamin D replacement is effective in chronic liver disease. Gastroenterol Clin Biol. 2010;34:618-620.
Putz-Bankuti C, Pilz S, Stojakovic T, et al. Association of 25-hydroxyvitamin D levels with liver dysfunction and mortality in chronic liver disease. Liver Int. 2012;32:845-851.
Barchetta I. Could vitamin d supplementation benefit patients with chronic liver disease? Gastroenterol Hepatol (N Y). 2012;8:755-757.
Kitson MT, Roberts SK. D-livering the message: the importance of vitamin D status in chronic liver disease. J Hepatol. 2012;57:897-909.
DiCecco SR, Wieners EJ, Wiesner RH, et al. Assessment of nutritional status of patients with end-stage liver disease undergoing liver transplantation. Mayo Clin Proc. 1989;64:95-102.
Singal AK, Kamath PS, Francisco Ziller N, et al. Nutritional status of patients with alcoholic cirrhosis undergoing liver transplantation: time trends and impact on survival. Transpl Int. 2013;26:788-794.
Stokes CS, Grunhage F, Baus C, et al. Vitamin D supplementation reduces depressive symptoms in patients with chronic liver disease. Clin Nutr. 2016;35:950-957.
Jorde R, Sneve M, Figenschau Y, et al . Effects of vitamin D supplementation on symptoms of depression in overweight and obese subjects: randomized double blind trial. Clin Nutr. 2016;35:950-957.
Manson JE, Bassuk SS, Lee IM, et al. The VITamin D and OmegA-3 TriaL (VITAL): rationale and design of a large randomized controlled trial of vitamin D and marine omega-3 fatty acid supplements for the primary prevention of cancer and cardiovascular disease. Contemp Clin Trials. 2012;33:159-171.